Compare NRK & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRK | ABUS |
|---|---|---|
| Founded | 2002 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 888.1M | 888.5M |
| IPO Year | N/A | N/A |
| Metric | NRK | ABUS |
|---|---|---|
| Price | $10.42 | $4.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 187.3K | ★ 2.1M |
| Earning Date | 01-01-0001 | 03-26-2026 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,606,000.00 |
| Revenue This Year | N/A | $125.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 116.64 |
| 52 Week Low | $8.95 | $2.71 |
| 52 Week High | $11.09 | $5.10 |
| Indicator | NRK | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 73.20 | 48.44 |
| Support Level | $10.19 | $3.85 |
| Resistance Level | $10.29 | $4.26 |
| Average True Range (ATR) | 0.05 | 0.33 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 100.00 | 58.18 |
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.